Top

Published in:

Open Access 01-05-2013 | Focussed Research Review

Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges

Authors: Pramod K. Srivastava, Fei Duan

Published in: Cancer Immunology, Immunotherapy | Issue 5/2013

Abstract

The idea that individual tumors are antigenically unique has been around since the very dawn of our recognition of adaptive immune response to tumors. That idea has inspired a small number of attempts at individualized immunotherapy of human cancers. Such previous attempts for solid tumors have been hobbled by an inability to define the individually unique antigenic repertoire of tumors because of technological difficulties. The new availability of rapid and cheap high throughput DNA sequencing promises to overcome that hurdle. Using this new ability, coupled with bio-informatic tools, it is now possible to define the immunogenic repertoire of any tumor to a high degree of granularity within a practical time frame and an acceptable cost. The development of these ideas, and a small number of such studies that underscore this promise, is discussed. This new way—of characterizing the tumor immunome through characterization of the tumor genome—has distinct challenges, including selection of the appropriate peptides, choosing methods of immunizations that can incorporate tens of epitopes, and addressing issues of antigenic heterogeneity of tumors. However, tools for meeting these challenges exist and are emergent.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCrossRef

Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372:145–154PubMedCrossRef

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422PubMedCrossRef

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647PubMedCrossRef

van der Bruggen P, Stroobant V, Vigneron N, Van den Eynde B (2012) Peptide database: T cell-defined tumor antigens. Cancer Immun. URL: http://www.cancerimmunity.org/peptide/

Srivastava PK (1996) Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Semin Immunol 8:295–302PubMedCrossRef

Buckwalter MR, Srivastava PK (2009) “It is the antigen(s), stupid” and other lessons from over a decade of vaccine therapy of human cancer. Semin Immunol 20:296–300CrossRef

Gilboa E (1999) The makings of a tumor rejection antigen. Immunity 11(3):263–270PubMedCrossRef

Ramarathinam L, Sarma S, Maric M, Zhao M, Yang G, Chen L, Liu Y (1995) Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol 155(11):5323–5329PubMed

10.

Huijbers IJ, Soudja SM, Uyttenhove C, Buferne M, Inderberg-Suso EM, Colau D, Pilotte L, Powis de Tenbossche CG, Chomez P, Brasseur F, Schmitt-Verhulst AM, Van den Eynde BJ (2012) Minimal tolerance to a tumor antigen encoded by a cancer-germline gene. J Immunol 188(1):111–121PubMedCrossRef

11.

Monach PA, Meredith SC, Siegel CT, Schreiber H (1995) A unique tumor antigen produced by a single amino acid substitution. Immunity 2:45–59PubMedCrossRef

12.

Dubey P, Hendrickson RC, Meredith SC, Siegel CT, Shabanowitz J, Skipper JCA, Engelhard VH, Hunt DF, Schreiber H (1997) The Immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD Box Helicase p68. J Exp Med 185:695–706PubMedCrossRef

13.

Noguchi Y, Chen YT, Old LJ (1994) A mouse mutant p53 product recognized by CD4 + and CD8 + T cells. Proc Natl Acad Sci USA 91(8):3171–3175PubMedCrossRef

14.

Ikeda H, Ohta N, Furukawa K, Miyazaki H, Wang L, Furukawa K, Kuribayashi K, Old LJ, Shiku H (1997) Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc Natl Acad Sci 94:6375–6379PubMedCrossRef

15.

Matsutake T, Srivastava PK (2001) The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci 98:3992–3997PubMedCrossRef

16.

Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44):16013–16018PubMedCrossRef

17.

Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769–778PubMed

18.

Klein G, Sjogren HO, Klein E, Hellstrom KE (1960) Demonstration of resistance against methylcholanthrene induced sarcomas in the primary autochthonous host. Cancer Res 20:1561–1572PubMed

19.

Globerson A, Feldman M (1964) Antigenic specificity of Benzo(a)Pyrene-induced sarcomas. J Natl Cancer Inst 32:1229–1243PubMed

20.

Basombrío MA (1970) Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res 30(10):2458–2462PubMed

21.

Basombrío MA, Prehn RT (1972) Antigenic diversity of tumors chemically induced within the progeny of a single cell. Int J Cancer 10(1):1–8PubMedCrossRef

22.

Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65(6):1349–1363PubMed

23.

Levy R, Robertson M, Leonard J (2008) Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared with non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non Hodgkin’s lymphoma (FNHL). Ann Oncol 19(suppl 4):iv101–iv102

24.

Freedman A, Neelapu SS, Nichols C et al (2009) Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 27:3036–3043PubMedCrossRef

25.

Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW (2011) Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29(20):2787–2794PubMedCrossRef

26.

Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150):345–350PubMedCrossRef

27.

Srivastava P (2002) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395–425PubMedCrossRef

28.

Suto R, Srivastava PK (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585–1588PubMedCrossRef

29.

Ishii T, Udono H, Yamano T, Ohta H, Uenaka A, Ono T, Hizuta A, Tanaka N, Srivastava PK, Nakayama E (1999) Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 162:1303–1309PubMed

30.

Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, Parmiani G (2001) Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 61(1):222–227PubMed

31.

Binder RJ, Han DK, Srivastava PK (2000) CD91: a receptor for heat shock protein gp96. Nat Immunol 1:151–155PubMedCrossRef

32.

Delneste Y, Magistrelli G, Gauchat J-F, Haeuw JF, Aubry J-P, Nakamura K, Kawakami-Honda N, Goetsch L, Sawamura T, Bonnefoy J-Y, Jeannin P (2002) Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17:353–362PubMedCrossRef

33.

Faries MB, Morton DL (2005) Therapeutic vaccines for melanoma: current status. BioDrugs 19(4):247–260PubMedCrossRef

34.

Srivastava PK (1993) Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res 62:153–177PubMedCrossRef

35.

Tomlinson I, Sasieni P, Bodmer W (2005) Commentary: how many mutations in a cancer? Am J Path 160:755–758CrossRef

36.

Simpson AJ (1997) The natural somatic mutation frequency and human carcinogenesis. Adv Cancer Res 71:209–240PubMedCrossRef

37.

Segal NH, Parsons DW, Peggs KS, Velculescu V et al (2008) Epitope landscape in breast and colorectal cancer. Cancer Res 68:889–892PubMedCrossRef

38.

Srivastava N, Srivastava PK (2009) Modeling the repertoire of true tumor-specific epitopes in a human cancer. PLoS ONE 4(7):e6094PubMedCrossRef

39.

Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, Huber C, Türeci O, Sahin U (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72(5):1081–1091PubMedCrossRef

40.

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400–404PubMedCrossRef

41.

Srivastava PK (2012) A vast new landscape of truly tumor-specific antigens: do they immunize and protect? 20th Annual International Cancer Immunotherapy Symposium of the Cancer Research Institute: From Milestones to Medicines, Translating tumor immunology Research into Immunotherapies. October 1–3

42.

Duitama J, Srivastava PK, Măndoiu II (2012) Towards accurate detection and genotyping of expressed variants from whole transcriptome sequencing data. BMC Genomics 13(Suppl 2):S6CrossRef

43.

Löwer M, Renard BY, de Graaf J, Wagner M, Paret C, Kneip C, Türeci O, Diken M, Britten C, Kreiter S, Koslowski M, Castle JC, Sahin U (2012) Confidence-based somatic mutation evaluation and prioritization. PLoS Comput Biol 8(9):e1002714PubMedCrossRef

44.

Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E (2006) Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 55(6):672–683PubMedCrossRef

45.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U (2011) Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 23(3):399–406PubMedCrossRef

46.

Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–92. Erratum in: (2012). N Engl J Med 367:976

47.

Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M (2011) Tumour evolution inferred by single-cell sequencing. Nature 472:90–94PubMedCrossRef

48.

Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107:18545–18550PubMedCrossRef

49.

Salk JJ, Fox EJ, Loeb LA (2010) Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol 5:51–75PubMedCrossRef

50.

Barker E, Mokyr MB (1987) Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan. Cancer Immunol Immunother 25(3):215–224PubMedCrossRef

51.

Zhang B, Karrison T, Rowley DA, Schreiber H (2008) IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 118(4):1398–1404PubMedCrossRef

52.

Lincoln A (1862) http://www.presidency.ucsb.edu/ws/index.php?pid=29503

53.

Brändle D, Bilsborough J, Rülicke T, Uyttenhove C, Boon T, Van den Eynde BJ (1998) The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol 28(12):4010–4019PubMedCrossRef

54.

Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM (1996) The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93(18):9730–9735PubMedCrossRef

Title: Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges
Authors: Pramod K. Srivastava
Fei Duan
Publication date: 01-05-2013
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 5/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-013-1422-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs

Specific humoral immune response to the Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the commensal bacterium Bacteroides ovatus D-6

Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen

Circulating tumor cells as therapy-related biomarkers in cancer patients

CD40 immunotherapy for pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer